Infliximab Treatment of Patients with Birdshot Retinochoroidopathy

Artornsombudh, Pichaporn; Gevorgyan, Ofelya; Payal, Abhishek R; Siddique, Sana S.; Foster, C. Stephen

doi:10.1016/j.ophtha.2012.05.048

Cited by 72 publications

(27 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[26][27][28][29] Regarding drug safety, anti-TNF-alpha medications may lead to an increased susceptibility to infection, including tuberculosis, immune-mediated side effects, in the likeness of atopic dermatitis, lupus-like reactions, and/or exacerbation of autoimmune diseases (e.g., multiple sclerosis), and hepatitis. [30][31][32][33][34][35][36] Thromboembolic incidents, congestive heart failure, and malignancies have also been described. 25,37 In addition, therapeutic efficacy may decrease over time secondary to the production of antibodies directed against the TNF-alpha inhibitor.…”

mentioning

confidence: 99%

Long-Term Efficacy of Systemic Infliximab in Recalcitrant Retinal Vasculitis

Sharma

Markov

Bajwa

et al. 2015

Retina

Self Cite

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

Long-Term Efficacy of Systemic Infliximab in Recalcitrant Retinal Vasculitis

Sharma

Markov

Bajwa

et al. 2015

Retina

Self Cite

View full text Add to dashboard Cite

show abstract

“…In the largest series to date of patients with BSCR treated with infliximab, nearly 90% of patients achieved complete control of inflammation after 1 year of treatment 63. Furthermore, patients with inactive inflammation at the outset of treatment were able to maintain disease quiescence with an acceptable side effect profile.…”

Section: Treatmentmentioning

confidence: 99%

Birdshot uveitis: current and emerging treatment options

Menezo¹,

Taylor²

2013

OPTH

View full text Add to dashboard Cite

Birdshot chorioretinopathy is a relatively uncommon subtype of idiopathic posterior uveitis with distinct clinical characteristics and a strong genetic association with the Human Leukocyte Antigen (HLA)-A29 allele. The diagnosis remains clinical and is based on the presence of typical clinical features, including multiple, distinctive, hypopigmented choroidal lesions throughout the fundus. The long-term visual prognosis of this disorder, however, remains guarded – central visual acuity can be preserved until late in the disease and it is not uncommon for patients to receive inadequate immunosuppressive treatment, leading to a poor long-term outcome in which peripheral retinal damage eventually leads to visual deterioration. Birdshot chorioretinopathy has proven a particularly attractive area of study within the field of uveitis, as it is a relatively easily defined disease with an associated human leukocyte antigen haplotype. Despite this, however, the immune mechanisms involved in its pathogenesis remain unclear, and some patients continue to lose retinal function despite therapy with corticosteroids and conventional immunosuppressive agents. Laboratory research continues to investigate the underlying mechanisms of disease, and clinical research is now being driven to improve the phenotyping and monitoring of this condition as, in the era of so-called personalized medicine, it is becoming increasingly important to identify patients at risk of visual loss early so that they can be treated more aggressively with targeted therapies such as the newer biological agents. This approach requires the formation of collaborative groups, as the relative rarity of the condition makes it difficult for one center to accumulate enough patients for worthwhile studies. Nevertheless, results obtained with newer therapies, such as biological agents directed against particular cytokines or cell-surface receptors, demonstrate ever improving control of the inflammation in refractory cases, providing hope that the outlook for visual function in this condition can only improve.

show abstract

“…Multiple investigators have reported the efficacy of infliximab in controlling intraocular inflammation, especially in patients with underlying systemic diseases such as Behçet disease and sarcoidosis. Additionally, infliximab has shown efficacy in controlling inflammation in cases with refractory uveitis . The 2018 EULAR Update recommended the use of infliximab as one of the first‐line agents in cases of initial or recurrent acute vision threatening ocular Bechet disease alongside corticosteroids .…”

Section: Current Therapiesmentioning

confidence: 99%

“…Additionally, infliximab has shown efficacy in controlling inflammation in cases with refractory uveitis. 84,89 The 2018 EULAR Update recommended the use of infliximab as one of the first-line agents in cases of initial or recurrent acute vision threatening ocular Bechet disease alongside corticosteroids. 90 Even though side effects were reported in 36% of the patients in one of the clinical trials, including pulmonary embolism, congestive heart failure, lupus-like reaction, vitreous haemorrhage and conversion to positive anti-nuclear antibody status, the 2-year continuation report did not find increased toxicity with prolonged use of infliximab.…”

Section: Infliximabmentioning

confidence: 99%

New therapies in development for the management of non‐infectious uveitis: A review

Hassan

Karkhur

Bae

et al. 2019

Clinical Exper Ophthalmology

View full text Add to dashboard Cite

Uveitis is a spectrum of inflammatory disorders characterized by ocular inflammation and is one of the leading causes of preventable visual loss. The main aim of the treatment of uveitis is to control the inflammation, prevent recurrences of the disease and preserve vision while minimizing the adverse effects associated with the therapeutic agents. Initial management of uveitis relies heavily on the use of corticosteroids. However, monotherapy with high‐dose corticosteroids is associated with side effects and cannot be maintained long term. Therefore, steroid‐sparing agents are needed to decrease the burden of steroid therapy. Currently, the therapeutic approach for non‐infectious uveitis (NIU) consists of a step‐ladder strategy with the first‐line option being corticosteroids in various formulations followed by the use of first‐, second‐ and third‐line agents in cases with suboptimal steroid response. Unfortunately, the agents currently at our disposal have limitations such as having a narrow therapeutic window along with their own individual potential side‐effect profiles. Therefore, research has been targeted to identify newer drugs as well as new uses for older drugs that target specific pathways in the inflammatory response. Such efforts are made in order to provide targeted and safer therapy with reduced side effects and greater efficacy. Several specially designed molecular antibodies are currently in various phases of investigations that can potentially halt the inflammation in patients with NIU. In the review, we have provided a comprehensive overview of the current and upcoming therapeutic options for patients with NIU.

show abstract

Infliximab Treatment of Patients with Birdshot Retinochoroidopathy

Cited by 72 publications

References 36 publications

Long-Term Efficacy of Systemic Infliximab in Recalcitrant Retinal Vasculitis

Long-Term Efficacy of Systemic Infliximab in Recalcitrant Retinal Vasculitis

Birdshot uveitis: current and emerging treatment options

New therapies in development for the management of non‐infectious uveitis: A review

Contact Info

Product

Resources

About